Capstone Therapeutics Announces Operating Update Conference Call
March 24 2014 - 2:29PM
Capstone Therapeutics (OTCQB:CAPS); (the
"Company"), will hold a conference call and webcast on Thursday,
March 27, 2014 at 4:30 pm EDT. The call may be accessed at
877-303-2908 (U.S.), 408-427-3860 (outside U.S.); accompanying
slides may be viewed by logging onto the Investors section of the
Company's website, www.capstonethx.com. A replay will be available
beginning March 27, 2014 at 7:30 pm EDT until midnight March 30,
2014, and may be accessed at 855-859-2056 (U.S.) or 404-537-3406
(outside U.S.) with conference ID 12618657.
About Capstone Therapeutics
Capstone Therapeutics is a biotechnology company committed to
developing a pipeline of novel therapeutic peptides aimed at
helping patients with under-served medical conditions. The Company
is focused on development and commercialization of two product
platforms: AZX100 and Apo E Mimetic Peptide Molecule AEM-28 and its
analogs (through the LipimetiX Development, LLC, joint
venture).
AZX100 is a novel synthetic 24-amino acid peptide, one of a new
class of compounds in the field of smooth muscle relaxation and
fibrosis. AZX100 has been evaluated for commercially significant
medical applications such as the prevention or reduction of
hypertrophic and keloid scarring and treatment of pulmonary and
peridural fibrosis.
Apolipoprotein E is a 299 amino acid protein that plays an
important role in lipoprotein metabolism. AEM-28 is a 28 amino acid
mimetic of Apo E that contains a domain that anchors into a
lipoprotein surface while also providing the Apo E receptor binding
domain, which allows clearance through the heparan sulfate
proteoglycan (HSPG) receptors (Syndecan-1) in the liver. AEM-28, as
an Apo E mimetic, has the potential to restore the ability of these
atherogenic lipoproteins to be cleared from the plasma, completing
the reverse cholesterol transport pathway, and thereby reducing
cardiovascular risk. This is an important mechanism of action for
AEM-28. For patients that lack LDL receptors (Homozygous Familial
Hypercholesterolemia, HoFH), or have Severe Refractory
Hypercholesterolemia, AEM-28 may provide a therapeutic
solution.
Capstone's corporate headquarters are in Tempe, Arizona. For
more information, please visit the Company's website:
www.capstonethx.com.
Statements in this press release or otherwise attributable to
Capstone regarding our business that are not historical facts are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve risks and uncertainties that could cause actual
results to differ materially from predicted results. These
risks include the factors discussed in our Form 10-K for the fiscal
year ended December 31, 2012 and other documents we file with the
U.S. Securities and Exchange Commission
Editor's Note: This press release is also
available under the Investors section of the Company's website at
www.capstonethx.com.
CONTACT: FOR FURTHER INFORMATION:
Investor Relations
(602) 286-5250
investorinquiries@capstonethx.com
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Capstone Therapeutics (QB) (USOTC:CAPS)
Historical Stock Chart
From Jul 2023 to Jul 2024